Adaptive Biotechnologies Corporation Common Stock Earnings Dividend

Adaptive Biotechnologies Corporation Common Stock’s revenue jumped 21.53% since last year same period to $71.55Mn in the Q2 2026. On a quarterly growth basis, Adaptive Biotechnologies Corporation Common Stock has generated 0.96% jump in its revenue since last 3-months.

Adaptive Biotechnologies Corporation Common Stock’s net profit fell -55.34% since last year same period to $-39.79Mn in the Q2 2026. On a quarterly growth basis, Adaptive Biotechnologies Corporation Common Stock has generated -98.61% fall in its net profits since last 3-months.

Adaptive Biotechnologies Corporation Common Stock’s net profit margin fell -27.82% since last year same period to -55.61% in the Q2 2026. On a quarterly growth basis, Adaptive Biotechnologies Corporation Common Stock has generated -96.73% fall in its net profit margins since last 3-months.

Adaptive Biotechnologies Corporation Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.1 - a 23.08% jump from last quarter’s estimates.

Adaptive Biotechnologies Corporation Common Stock’s earning per share (EPS) estimates for the current year stand at -0.1.

Adaptive Biotechnologies Corporation Common Stock’s earning per share (EPS) jumped 41.18% since last year same period to -0.1 in the Q2 2026. This indicates that the Adaptive Biotechnologies Corporation Common Stock has generated 41.18% annual rate of jump in its earning per share (EPS) in the last 4 quarters.